Table 1. Subject baseline characteristics and one-year stroke recurrence according to the presence of metabolic syndromea.
| Metabolic syndrome (n = 1355) | No metabolic syndrome (n = 1284) | P valueb | |
| Female (%) | 44.2 | 27.3 | 0.00 |
| Median Age (interquartile range), years | 62 (53–72) | 64 (54–74) | 0.01 |
| Smoker (current or former) (%) | 39.5 | 47.3 | 0.00 |
| History of atrial fibrillation (%) | 5.3 | 7.8 | 0.01 |
| History of coronary heart disease (%) | 15.1 | 12.5 | 0.05 |
| Median NIHSSh at admission (interquartile range) | 4 (2–8) | 4 (2–8) | 0.65 |
| Elevated waist circumferenced (%) | 73.2 | 23.4 | 0.00 |
| Elevated TGe (%) | 60.8 | 13.9 | 0.00 |
| Low HDL-Cf (%) | 65.6 | 22.8 | 0.00 |
| Elevated BPc (%) | 87.5 | 60.4 | 0.00 |
| Elevated fasting blood glucoseg (%) | 73.8 | 27.1 | 0.00 |
| Stroke recurrence | 21.5 | 12.4 | 0.00 |
BP, blood pressure; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; NIHSS. National Institutes of Health Stroke Scale.
a
Metabolic syndrome was defined by the International Diabetes Federation (IDF) criteria.
b
Wilcoxon rank sum tests and Pearson Chi square tests used for continuous and categorical variables, respectively.
c
Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, or medication.
d
Waist circumference ≥80 cm for women or ≥90 cm for men.
e
Triglyceride level ≥150 mg/dL, or medication.
f
HDL-C level ≤50 mg/dL for women or ≤40 mg/dL for men, or medication.
g
Fasting glucose level ≥100 mg/dL or medication for elevated glucose or antidiabetic medication.
h
Neurologic impairment.